| 1 | 08:00-08:10 | 致辞 |
开幕致辞 |
|
||||||||
| 2 | 08:10-08:17 | 口头报告 |
Peritoneal effusion as a marker of disease severity in secondary hemophagocytic lymphohistiocytosis: clinical and immunological insights |
|
||||||||
| 3 | 08:17-08:24 | 口头报告 |
Multicenter Validation and Optimization of the Hemophagocytic Lymphohistiocytosis Threshold Model |
|
||||||||
| 4 | 08:24-08:31 | 口头报告 |
Epigenetic dysregulation of pseudogene ZNF300P1 predicts advanced stage and aggressive phenotype in myelodysplastic neoplasms and acute myeloid leukemia |
|
||||||||
| 5 | 08:31-08:38 | 口头报告 |
PRKCE maintains BCR signaling dependency and cell-cycle adaptation to drive BTK inhibitor resistance in Waldenström Macroglobulinemia |
|
||||||||
| 6 | 08:38-08:45 | 口头报告 |
PHF19 Drives IMiDs Resistance by A Reciprocal Epigenetic-transcriptional Adaptive Circuit in Multiple Myeloma |
|
||||||||
| 7 | 08:45-08:50 |
第一组专家点评 |
|
|||||||||
| 8 | 08:50-08:57 | 口头报告 |
Clinical characteristics and molecular heterogeneity of EBV-positive lymphoma |
|
||||||||
| 9 | 08:57-09:04 | 口头报告 |
Prognostic Relevance of Residual-Based Discordance Between Serum Soluble B-Cell Maturation Antigen and Tumor-Burden Surrogates in Newly Diagnosed Multiple Myeloma |
|
||||||||
| 10 | 09:04-09:11 | 口头报告 |
Unraveling chronic myelomonocytic leukemia (CMML): clinical and therapeutic insights from a ten-year multi-center retrospective cohort |
|
||||||||
| 11 | 09:11-09:18 | 口头报告 |
Subtype distribution and co-mutation landscape of CSF3R mutations in myeloid neoplasms: a multicenter retrospective study |
|
||||||||
| 12 | 09:18-09:25 | 口头报告 |
Blood Metagenomic Next-Generation Sequencing Reveals Prognostic Patterns in Mucormycosis and Guides Antifungal Therapy |
|
||||||||
| 13 | 09:25-09:30 | 点评 |
第二组专家点评 |
|
||||||||
| 14 | 09:30-09:37 | 口头报告 |
Clinical Characteristics of Primary Central Nervous System Diffuse Large B-Cell Lymphoma germinal center B-cell-like Subtype |
|
||||||||
| 15 | 09:37-09:44 | 口头报告 |
Augmenter of Liver Regeneration Suppresses Ferroptosis via the AMPK/SREBP1/FADS2 Axis to Promote Chemoresistance in T-ALL |
|
||||||||
| 16 | 09:44-09:51 | 口头报告 |
Multi-Omics Reveals the Immune Microenvironment of Ruxolitinib-Resistant Primary Myelofibrosis and the Preclinical Efficacy of CDK2 Inhibitor-Based Combinations against Myeloproliferative Neoplasms Transformed to AML |
|
||||||||
| 17 | 09:51-09:58 | 口头报告 |
Clinical phenotype, in-hospital mortality, and treatment pathways in thrombotic thrombocytopenic purpura: a two-decade single-centre cohort study |
|
||||||||
| 18 | 09:58-10:03 | 点评 |
第三组专家点评 |
|
||||||||
| 19 | 10:03-10:10 | 口头报告 |
Venetoclax plus azacitidine and lenalidomide (VAL) for newly diagnosed elderly patients with acute myeloid leukemia/myelodysplastic syndromes: a single-center, prospective, single-arm clinical study |
|
||||||||
| 20 | 10:10-10:17 | 口头报告 |
Preliminary Study on the Effects and Mechanisms of Hedyotis diffusa Willd. against Acute Myeloid Leukemia Based on Network Pharmacology, Molecular Docking and in Vitro Experimental Validation |
|
||||||||
| 21 | 10:17-10:24 | 口头报告 |
Venetoclax plus azacitidine and cytarabine in younger unfit patients with newly AML: A cohort from a multi-centre, open-label, single-arm, phase 2 trial |
|
||||||||
| 22 | 10:24-10:31 | 口头报告 |
β-sitosterol suppresses JAK2-driven myeloproliferative neoplasm cell growth in association with STAT1 upregulation and BCL-2 downregulation |
|
||||||||
| 23 | 10:31-10:38 | 口头报告 |
Systemic Mastocytosis in China: A Multicenter Real-World Study of Clinical Features, Molecular Alterations, Treatment Patterns, and Survival Outcomes |
|
||||||||
| 24 | 10:38-10:43 | 点评 |
第四组专家点评 |
|
||||||||
| 25 | 10:43-10:50 | 口头报告 |
Addition of a FLT3 inhibitor to hypomethylating therapy plus venetoclax in newly diagnosed, unfit FLT3-ITD acute myeloid leukaemia: a multicentre retrospective study |
|
||||||||
| 26 | 10:50-10:57 | 口头报告 |
Etoposide plus thiotepa-busulfan-fludarabine conditioning for allogeneic transplantation in high-risk EBV-associated NK/T-cell malignancies |
|
||||||||
| 27 | 10:57-11:04 | 口头报告 |
Early intervention with the oropharyngeal probiotic BP-OM1 for infection prophylaxis in patients with diffuse large B-cell lymphoma undergoing autologous haematopoietic stem-cell transplantation: a multicentre observational study |
|
||||||||
| 28 | 11:04-11:11 | 口头报告 |
Latent Classes and Influencing Factors of Fear of Cancer Recurrence before Hematopoietic Stem Cell Transplantation |
|
||||||||
| 29 | 11:11-11:16 | 点评 |
第五组专家点评 |
|
||||||||
| 30 | 11:16-11:23 | 口头报告 |
Pre-clinical development of CAR-T cells targeting a lytic EBV antigen gp350 for therapy of EBV-positive diffuse large B-cell lymphoma |
|
||||||||
| 31 | 11:23-11:30 | 口头报告 |
Efficacy and safety of a novel third-generation fully humanized tandem CD19/CD22 dual-targeted CAR-T with TLR2 costimulation for relapsed/refractory diffuse large B-cell lymphoma |
|
||||||||
| 32 | 11:30-11:37 | 口头报告 |
Efficacy of Inati-cel Consolidation Therapy in Allogeneic Transplant-Ineligible Adolescent and Adult Patients with B-ALL |
|
||||||||
| 33 | 11:37-11:44 | 口头报告 |
Sexual health status and nursing needs of lymphoma patients during treatment: gender differences |
|
||||||||
| 34 | 11:44-11:49 | 点评 |
第六组专家点评 |
|
||||||||
| 35 | 11:49-11:56 | 总结 |
总结 |
|
||||||||